

Basal Insulin Therapy in the Treatment of Insulin Resistant Type 2 Diabetes: The Role of the Pharmacist in Ensuring Their Safe and Effective Use in Patients

September 2, 2015
6:30pm—7:30pm

Cover-3 @ Village Shopping Center
2700 W Anderson Ln #202
Austin, TX 78757

Curtis Triplitt, PharmD, CDE

Texas Diabetes Institute, University Health System
Associate Professor of Medicine, Clinical
Division of Diabetes
University of Texas Health Science Center at San Antonio
San Antonio, TX

Online Registration: <http://bit.ly/1TqSQO2>

Activity Overview

The educational series will focus the use of high concentration insulin formulations in the treatment of type 2 diabetes. Faculty will discuss the clinical, pharmacokinetic and pharmacodynamic profiles for current and emerging basal insulins as well as currently available insulin pens and syringes used for the administration of insulin. Additionally, faculty will provide instruction regarding strategies for safely converting between U-100 and concentrated insulin formulations using different syringes and pen devices.

Purpose

Currently numerous medication errors are being made in the use and dosing of U-500 insulin due to the lack of a U-500 scale syringe. It is important for pharmacists to be familiar with the availability of the various insulin pens and syringes and to be able to determine the appropriate pen or syringe for different insulin concentrations. Additionally, pharmacists need to be well versed on the PK/PD profiles and evidence with current and emerging basal insulins in order to counsel patients on the safe and effective use of these insulins. Insulin is the most effective agent available for the treatment of hyperglycemia. However, weight gain, hypoglycemia, and various other barriers limit the success of insulin-mediated glucose control. Thus, it is important that pharmacists be able to apply strategies to the barriers to insulin-mediated glucose

Accreditation Statement

The University of the Pacific, Thomas J. Long School of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is accredited for a maximum of 2.0 hours of continuing education credit (.20 CEU) for pharmacists and is numbered 0006-0000-15-013-L01-P.

This program is organized by Horizon CME.

Supported by an independent educational grants from Sanofi –aventis U.S.

There is no fee for this educational activity

Target Audience

This CME initiative will target pharmacy professionals.

Activity Learning Objectives

After completing this activity, clinician participants should be able to:

- Describe the reasons for the use of high concentration insulin formulations in the treatment of type 2 diabetes
- Discuss the clinical, pharmacokinetic and pharmacodynamic profiles for current and emerging basal insulins
- Implement strategies for safely converting between U-100 and concentrated insulin formulations using different syringes and pen devices in patients with type 2 diabetes
- Review currently available insulin pens and syringes

Credit Designation

To receive continuing education credit for this program, participants must attend the conference, complete the Pre- and Post-Activity, ARS surveys, and submit an activity evaluation which will be provided to you via email following the live activity. Once your evaluation is received statements of credit will be uploaded to participant NABP e-profiles via CPE Monitor within 30 days of completion of the program. Paper statements will not be mailed. These are ongoing programs with an initial release date of 04.24.15.

Jointly Provided By

